Effect of gefitinib on growth of human lung cancer cell line A549

PDF(529 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2012, Vol. 23 ›› Issue (5) : 392-394.

JIANG Xuedong¹, ZHU Jiang², LIU Changhao¹, QUAN Liguo¹, and WANG Guozhu¹.

Author information +

History +

Abstract

Objective To investigate the effect of gefitinib on the growth of human lung cancer cell line A549 and its molecular machenism. Methods The growth suppressing effect of gefitinib on A549 was quantified by MTT assay. Apoptosis was assayed with annexinⅤ-FITC/PI doubled stained flow cytometry. Western blotting assay was adopted to identify the expression of STAT3. Results After treatment with gefitinib, MTT showed that cell proliferation was inhibited, and the highest inhibitory rate was (80.20±0.45)% ( P ＜0.05). AnnexinⅤ-FITC/PI doubled stained flow cytometry showed that the cell apoptosis rate was (41.39±1.74)%, rising remarkably ( P ＜0.05). Western blotting showed significant decline of expression of STAT 3. Conclusions Gefitinib can significantly inhibit the growth of human lung cancer cell line A549 and induce early apoptosis. The effect may be due to the down-regulation of STAT 3 expression.

Key words

gefitinib / lung cancer / proliferation / apoptosis / signal transducer and activator of transcription 3

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Effect of gefitinib on growth of human lung cancer cell line A549[J]. Medical Journal of the Chinese People Armed Police Forces. 2012, 23(5): 392-394

References

［1］Harichand-HerdtS,RamalingamSS.Targetedtherapyforthetreatmentofnon-smallcelllungcancer:focusoninhibitionofepidermalgrowthfactorreceptor［J］.SeminThoracCardiovascSurg,2008,20(3):217-223.

［2］BansalN,YendluriV,WenhamRM.Themolecularbiologyofendometrialcancersandtheimplicationsforpathogenesis,classification,andtargetedtherapies［J］.CancerControl,2009,16(1):8-13.

［3］JinQ,EstevaFJ.Cross-talkbetweentheErbB/HERfamilyandthetypeIinsulin-likegrowthfactorreceptorsignalingpathwayinbreastcancer［J］.JMammaryGlandBiolNeoplasia,2008,13(4):485-498.

［4］SawyersC.Targetedcancertherapy［J］.Nature,2004,432(70):294-297.

［5］SalomonDS,BrandtR,CiardielloF,etal.Epidermaigrowthfactor-relatedpeptidesandtheirreceptorsinhumanmalignancies［J］.CritRevOncolHematol,1995,19(3):183-232.

［6］〖KG-0.7mm〗WestHJ.Noveltargetedagentsforlungcancer［J］.ClinLungCancer,2009,10(1):41-46.

［7］〖KG-0.7mm〗JoyAA,ButtsCA.Extendingoutcomes:epidermalgrowthfactorreceptor-targetedmonoclonalantibodiesinnon-small-celllungcancer［J］.ClinLungCancer,2009,10(1):24-29.

［8］PakkalaS,RamalingamSS.Combinedinhibitionofvescularendothelialgrowthfactorandepidermalgrowthfactorsignalinginnon-small-celllungcancertherapy［J］.ClinLungCancer,2009,10(1):17-23.

［9］PennellNA,LynchTJ.CombinedinhibitionoftheVEGFRandEGFRsignalingpathwaysinthetreatmentofNSCLC［J］.Oncologist,2009,14(4):399-411.

［10］〖JP4〗BlackledgeG,AverbuchS.Genifitinib(‘Iressa’,ZD1839)andnewepidermalgrowthfactorreceptorinhibitors［J］.BrJCancer,2004,90(3):566-572.

［11］〖JP3〗LinCC,YangCH.Epidermalgrowthfactorreceptortyrosinekinaseinhibitorsinelderlyorpoorperformancestatuspatientswithadvancednon-smallcelllungcancer［J］.TargetOncol,2009,4(1):37-44.

［12］〖JP3〗LiJ,LiY,FengZ,etal.Anti-tumoractivityofanovelEGFRtyrosinekinaseinhibitoragainsthumanNSCLCinvitroandinvivo［J］.CancerLett,2009,279(2):213-220.